Results 91 to 100 of about 139,249 (224)

Intravenous immunoglobulin as an adjunct to phototherapy in neonatal haemolytic disease: A systematic review and meta‐analysis

Transfusion Medicine, EarlyView.
Abstract Phototherapy remains the first‐line treatment of haemolytic disease of the newborn (HDN), a potentially life‐threatening condition caused by maternal alloimmunisation. Intravenous immunoglobulin (IVIG) has been proposed as an adjunct to reduce the need for exchange transfusion (ET), a procedure associated with significant risks.
Megan Roberts, James W. F. Burns, Alma Sato, Dafni‐Stravroula Grammenou, Emily E. Lugard, May Y. Hajeir, Lamees M. Al Darwashi, David Riese, Eleanor Froneman, Christian A. Than, Hayato Nakanishi, Sandeep Potluri   +11 more
wiley   +1 more source

Transplantation rénale ABO incompatible

, 2012
ABO-incompatible living donor renal transplantation began in 1982. It may provide a significant source of organs. One dose of rituximab is given four weeks pre-operatively and oral triple immunosuppressive regimen is introduced 7 days pre-operatively ...
Hadaya, Karine
core  

The predictive value of blood neutrophil-lymphocyte ratio in patients with end-stage liver cirrhosis following ABO-incompatible liver transplantation

Journal of Research in Medical Sciences, 2016
Background: The study was designed to assess the role of preoperative neutrophil, lymphocyte, and neutrophil-lymphocyte ratio (NLR) in predicting survival outcomes of ABO-incompatible liver transplantation (LT).
Bingyi Lin, Lei Geng, Zhiyun Zheng, Junjun Jia, Tian Shen, Jing Zhang, Lin Zhou, Shusen Zheng   +7 more
doaj   +1 more source

An update on ABO-incompatible kidney transplantation

Transplant International, 2014
ABO-incompatible kidney transplantation is nowadays a well-established procedure to expand living donor transplantation to blood group incompatible donor/recipient constellations. In the last two decades, transplantation protocols evolved to more specific isohaemagglutinin elimination techniques and established competent antirejection protection ...
Zschiedrich, Stefan, Kramer-Zucker, Albrecht, Jänigen, Bernd, Seidl, Theodor Maximilian, Emmerich, Florian, Pisarski, Przemyslaw, Huber, Tobias B.   +6 more
openaire   +3 more sources

AABB survey on directed blood donation practices

Transfusion, EarlyView.
Abstract Background Standardized guidance regarding the processes for collecting directed blood donations (DBD) is lacking, leading to variable practices. This study assessed laboratory, clinical, and charging practices for DBD collection in the United States and Canada. Study Design and Methods An electronic survey was distributed to United States and
Nabiha H. Saifee, Emily Coberly, Brian D. Adkins, Louise Helander, Nancy Robitaille, Laura K. Dilly, Lani Lieberman   +6 more
wiley   +1 more source

ABO-incompatible organ and bone marrow transplantation: current status

, 2003
Despite the presence of preformed antibodies against AB oligosaccharide epitopes on the donor vascular endothelium, approximately one-third of ABO-incompatible organ allografts are not rejected by a humoral mechanism. With the growing immune-manipulation
Cooper, David K C, Wu, Anette, Buehler, Leo Hans   +2 more
core   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

Transfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman, Meghana Vivek, Rida Hasan, Siobán Keel, Laura Connelly‐Smith   +4 more
wiley   +1 more source

ABO incompatible renal transplant: Transfusion medicine perspective

Asian Journal of Transfusion Science, 2017
Introduction: Our study presents an analysis of the trends of ABO antibody titers and the TPE (Therapeutic Plasma Exchange) procedures required pre and post ABO incompatible renal transplant.
Raj Nath Makroo, Sweta Nayak, Mohit Chowdhry, Sanjiv Jasuja, Gaurav Sagar, N L Rosamma, Uday Kumar Thakur   +6 more
doaj   +1 more source

Implementation of soluble CD38 in blood crossmatching for patients on anti‐CD38 therapy: A single‐center experience

Transfusion, EarlyView.
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht, David Hanna, Grishma Amatya Jaspau, Ravi Sarode   +3 more
wiley   +1 more source

The Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient: The Swiss Experience. [PDF]

, 2015
BACKGROUND We developed a multicentric Swiss protocol for ABO-incompatible kidney transplantation including immunoadsorption column reuse. The aim of this study was to assess efficacy and safety of immunoadsorption column reuse in ABO-incompatible ...
Binet, Isabelle, Huynh-Do, Uyen, Schiesser, Marc, Dickenmann, Michael, Eisenberger, Ute, Fehr, Thomas, Steinemann, Daniel C, Hadaya, Karine, Schiesser M, Eisenberger U, Hadaya K, Fehr T, Steinemann DC, Binet I, Dickenmann M, Huynh-Do U   +15 more
core   +2 more sources